CN102026634A - 诱导肿瘤缺氧以治疗癌症 - Google Patents
诱导肿瘤缺氧以治疗癌症 Download PDFInfo
- Publication number
- CN102026634A CN102026634A CN2009801027827A CN200980102782A CN102026634A CN 102026634 A CN102026634 A CN 102026634A CN 2009801027827 A CN2009801027827 A CN 2009801027827A CN 200980102782 A CN200980102782 A CN 200980102782A CN 102026634 A CN102026634 A CN 102026634A
- Authority
- CN
- China
- Prior art keywords
- tumor
- stilbene
- hypoxia
- tirapazamine
- described method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310699012.3A CN104043125B (zh) | 2008-04-10 | 2009-04-08 | 诱导肿瘤缺氧以治疗癌症 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4396408P | 2008-04-10 | 2008-04-10 | |
US61/043,964 | 2008-04-10 | ||
PCT/US2009/039899 WO2009126705A2 (en) | 2008-04-10 | 2009-04-08 | Induction of tumor hypoxia for cancer therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310699012.3A Division CN104043125B (zh) | 2008-04-10 | 2009-04-08 | 诱导肿瘤缺氧以治疗癌症 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102026634A true CN102026634A (zh) | 2011-04-20 |
CN102026634B CN102026634B (zh) | 2014-01-22 |
Family
ID=41162569
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980102782.7A Active CN102026634B (zh) | 2008-04-10 | 2009-04-08 | 诱导肿瘤缺氧以治疗癌症 |
CN201310699012.3A Active CN104043125B (zh) | 2008-04-10 | 2009-04-08 | 诱导肿瘤缺氧以治疗癌症 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310699012.3A Active CN104043125B (zh) | 2008-04-10 | 2009-04-08 | 诱导肿瘤缺氧以治疗癌症 |
Country Status (7)
Country | Link |
---|---|
US (4) | US8591921B2 (zh) |
JP (2) | JP5731372B2 (zh) |
KR (1) | KR101925436B1 (zh) |
CN (2) | CN102026634B (zh) |
HK (1) | HK1202057A1 (zh) |
TW (1) | TWI504391B (zh) |
WO (1) | WO2009126705A2 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512692A (zh) * | 2012-01-16 | 2012-06-27 | 北京大学 | 肿瘤靶向栓塞治疗组合物及其制备方法 |
CN107007571A (zh) * | 2017-02-24 | 2017-08-04 | 福州市传染病医院 | 肿瘤微酸性敏感的铜‑药物共配位自组装纳米粒及应用 |
CN108348463A (zh) * | 2016-05-13 | 2018-07-31 | 泰克利森有限公司 | 用于治疗肝脏组织的方法 |
CN108472366A (zh) * | 2015-10-21 | 2018-08-31 | 泰克利森有限公司 | 用于免疫介导的癌症疗法的组合物和方法 |
CN110051848A (zh) * | 2019-05-06 | 2019-07-26 | 中国科学院长春应用化学研究所 | 药物组合、应用以及抗肿瘤的药物 |
CN112961082A (zh) * | 2021-02-22 | 2021-06-15 | 沈阳药科大学 | 一种血管阻断剂与双载药仿生脂质体联用的给药系统 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2389532T3 (es) | 2005-06-29 | 2012-10-29 | Threshold Pharmaceuticals, Inc. | Profármacos alquilantes de fosforamidato |
CN102026634B (zh) | 2008-04-10 | 2014-01-22 | 弗吉尼亚州立邦联大学 | 诱导肿瘤缺氧以治疗癌症 |
EP3311835B1 (en) * | 2010-07-12 | 2021-03-24 | Threshold Pharmaceuticals Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
EP2407161A1 (en) * | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
US9402820B2 (en) | 2011-04-22 | 2016-08-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors |
EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA ACTIVATED DRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
CA2930001A1 (en) * | 2013-11-11 | 2015-05-14 | University Hospitals Cleveland Medical Center | Targeted treatment of anerobic cancer |
US9586056B2 (en) * | 2014-07-03 | 2017-03-07 | Haniva Llc | Combination therapy for treating cancer and method for treating cancer using a combination therapy |
EP3177713B1 (en) * | 2014-08-08 | 2020-08-05 | Poseida Therapeutics, Inc. | Compositions and their use for inducing nanoparticle-mediated microvascular embolization of tumors |
EP3250215A4 (en) | 2015-01-29 | 2018-08-08 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
US20180127748A1 (en) * | 2015-05-15 | 2018-05-10 | The General Hospital Corporation | Methods relating to the prevention and treatment of drug resistance |
US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
WO2017190091A1 (en) | 2016-04-29 | 2017-11-02 | Vindico Nanobiotechnology, Llc | Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids |
CN110585214A (zh) * | 2019-09-25 | 2019-12-20 | 湖北大学 | 一种促进治疗肿瘤效果的纳米粒子及其合成方法 |
CN110713596B (zh) * | 2019-11-08 | 2022-04-29 | 西北师范大学 | 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成 |
CN114344482B (zh) * | 2022-01-14 | 2023-05-12 | 重庆医科大学附属第二医院 | 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用 |
WO2024006901A1 (en) * | 2022-06-29 | 2024-01-04 | Diffusion Pharmaceuticals Llc | Uses of bipolar trans carotenoids in the treatment of cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980779A (en) | 1972-02-01 | 1976-09-14 | Bayer Aktiengesellschaft | 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same |
US5616584A (en) | 1986-09-25 | 1997-04-01 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
DE69434048T2 (de) | 1993-07-19 | 2005-10-06 | Angiotech Pharmaceuticals, Inc., Vancouver | Anti-angiogene Mittel und Verfahren zu deren Verwendung |
US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
GB9404400D0 (en) | 1994-03-07 | 1994-04-20 | Wood Pauline J | Potentiation of bioreductive agents |
PT1014990E (pt) | 1997-03-07 | 2006-11-30 | Sanofi Aventis Us Llc | Associação antitumoral de 1, 4-dióxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platina. |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
EP1435908A4 (en) | 2001-09-13 | 2006-03-15 | Korea Inst Sci & Tech | OILY PACLITAXEL COMPOSITION AND FORMULATION FOR CHEMOEMOLISATION AND METHOD OF MANUFACTURING THEREOF |
US20060276527A1 (en) * | 2003-01-17 | 2006-12-07 | Thresold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
WO2004075904A1 (en) | 2003-02-26 | 2004-09-10 | Pharmacia Italia Spa | Method for treating liver cancer by intrahepatic administration of nemorubicin |
ITRM20030355A1 (it) | 2003-07-18 | 2005-01-19 | Sigma Tau Ind Farmaceuti | Composti ad attivita' citotossica derivati della combretastatina. |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
CN102026634B (zh) | 2008-04-10 | 2014-01-22 | 弗吉尼亚州立邦联大学 | 诱导肿瘤缺氧以治疗癌症 |
-
2009
- 2009-04-08 CN CN200980102782.7A patent/CN102026634B/zh active Active
- 2009-04-08 KR KR1020107025113A patent/KR101925436B1/ko active IP Right Grant
- 2009-04-08 US US12/922,658 patent/US8591921B2/en active Active
- 2009-04-08 JP JP2011504152A patent/JP5731372B2/ja active Active
- 2009-04-08 WO PCT/US2009/039899 patent/WO2009126705A2/en active Application Filing
- 2009-04-08 CN CN201310699012.3A patent/CN104043125B/zh active Active
- 2009-04-09 TW TW098111832A patent/TWI504391B/zh active
-
2013
- 2013-10-01 US US14/043,661 patent/US9649316B2/en active Active
-
2015
- 2015-01-07 JP JP2015001834A patent/JP5944018B2/ja active Active
- 2015-03-12 HK HK15102548.6A patent/HK1202057A1/zh unknown
-
2017
- 2017-04-05 US US15/480,250 patent/US10426779B2/en active Active
- 2017-04-05 US US15/480,242 patent/US10159676B2/en active Active - Reinstated
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
Non-Patent Citations (2)
Title |
---|
DAVID DURRANT 等: "cis-3, 4", 5-Trimethoxy-3"-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion", 《CANCER CHEMOTHER PHARMACOLOGY》 * |
STEPHEN CLIFFE等: "Combining Bioreductive Drugs (SR 4233 or SN 23862) With The Vasoactive Agents Flavone Acetic Acid or 5,6-Dimethylxanthenone Acetic Acid", 《INT. J. RADIATION ONCOLOGY BIOL. PHYS.》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512692A (zh) * | 2012-01-16 | 2012-06-27 | 北京大学 | 肿瘤靶向栓塞治疗组合物及其制备方法 |
CN102512692B (zh) * | 2012-01-16 | 2014-07-16 | 北京大学 | 肿瘤靶向栓塞治疗组合物及其制备方法 |
CN108472366A (zh) * | 2015-10-21 | 2018-08-31 | 泰克利森有限公司 | 用于免疫介导的癌症疗法的组合物和方法 |
US11534445B2 (en) | 2015-10-21 | 2022-12-27 | Teclison Limited | Compositions and methods for immune-mediated cancer therapy |
CN108348463A (zh) * | 2016-05-13 | 2018-07-31 | 泰克利森有限公司 | 用于治疗肝脏组织的方法 |
CN107007571A (zh) * | 2017-02-24 | 2017-08-04 | 福州市传染病医院 | 肿瘤微酸性敏感的铜‑药物共配位自组装纳米粒及应用 |
CN110051848A (zh) * | 2019-05-06 | 2019-07-26 | 中国科学院长春应用化学研究所 | 药物组合、应用以及抗肿瘤的药物 |
CN112961082A (zh) * | 2021-02-22 | 2021-06-15 | 沈阳药科大学 | 一种血管阻断剂与双载药仿生脂质体联用的给药系统 |
Also Published As
Publication number | Publication date |
---|---|
JP2015110602A (ja) | 2015-06-18 |
TWI504391B (zh) | 2015-10-21 |
TW201002312A (en) | 2010-01-16 |
US9649316B2 (en) | 2017-05-16 |
US10426779B2 (en) | 2019-10-01 |
WO2009126705A8 (en) | 2011-04-14 |
KR101925436B1 (ko) | 2018-12-05 |
JP5731372B2 (ja) | 2015-06-10 |
WO2009126705A2 (en) | 2009-10-15 |
KR20110050583A (ko) | 2011-05-16 |
CN102026634B (zh) | 2014-01-22 |
WO2009126705A3 (en) | 2010-02-18 |
US8591921B2 (en) | 2013-11-26 |
US20140065139A1 (en) | 2014-03-06 |
US20120087913A1 (en) | 2012-04-12 |
US10159676B2 (en) | 2018-12-25 |
CN104043125A (zh) | 2014-09-17 |
US20180050039A1 (en) | 2018-02-22 |
JP5944018B2 (ja) | 2016-07-05 |
JP2011516565A (ja) | 2011-05-26 |
US20170224693A1 (en) | 2017-08-10 |
HK1202057A1 (zh) | 2015-09-18 |
CN104043125B (zh) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102026634B (zh) | 诱导肿瘤缺氧以治疗癌症 | |
Koukourakis et al. | Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study | |
CN109982698A (zh) | 治疗癌性肿瘤的方法 | |
Symon et al. | Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model | |
Zhou et al. | 64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor | |
JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
Spiegelberg et al. | Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity | |
Kunieda et al. | Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer | |
CN102170881B (zh) | 用于肾脏细胞癌的治疗的3,3’,4,4’-四羟基-2,2’-联吡啶-n,n’-二氧化物 | |
KR20010052305A (ko) | 약제 조성물 | |
Avritscher et al. | Transcatheter intra-arterial limb infusion for extremity osteosarcoma: technical considerations and outcomes | |
Kawakami et al. | Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas | |
Liu et al. | A rat toxicological study of intra-arterial injection of tirapazamine, a hypoxia-activating cancer therapeutic agent, followed by hepatic artery ligation | |
Storm et al. | Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma | |
Schwade et al. | Clinical experience with intravenous misonidazole for carcinoma of the esophagus: results in attempting radiosensitization of each fraction of exposure | |
JP2015091766A (ja) | 癌治療支援システム | |
NZ615005B2 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
UA15986U (en) | Method for treating patients with non-resectable ovarian cancer metastases to liver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LEE PECK-SUN Effective date: 20130902 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130902 Address after: Virginia Applicant after: Univ Virginia Commonwealth Address before: Virginia Applicant before: Univ Virginia Commonwealth Applicant before: P .lin |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: R *li Inventor after: P *lin Inventor before: R .li Inventor after: Li Ruimin Inventor after: Lin Baisun Inventor before: R *li Inventor before: P *lin |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LEE RONALD LEE PECK-SUN TO: LI RUIMIN LIN BAISUN Free format text: CORRECT: INVENTOR; FROM: LEE RONALD TO: LEE RONALD LEE PECK-SUN |